|
At the day of ICU admission
|
|
Age, years
|
63.9 ± 15.2
|
65.3 ± 13.3
|
61.8 ± 17.6
|
0.476
|
|
Male, n (%)
|
25 (60)
|
15 (63)
|
10 (59)
|
> 0.999
|
|
BMI
|
21.8 ± 5.8
|
22.1 ± 7.0
|
21.3 ± 3.8
|
0.657
|
|
SOFA score
|
15 (12–16)
|
13 (12–15)
|
16 (14–19)
|
0.009
|
|
APACHE II score
|
33 (29–39)
|
36 (30–39)
|
32 (27–37)
|
0.597
|
|
Creatinine, mg/dL
|
1.46 (0.93–2.29)
|
1.82 (0.92–2.39)
|
1.20 (0.99–1.71)
|
0.327
|
|
Bilirubin, mg/dL
|
1.4 (0.9–4.4)
|
1.05 (0.8–1.6)
|
1.7 (1.1–7.3)
|
0.065
|
|
Platelet count
|
71 (44–119)
|
105 (54–176)
|
50 (25–71)
|
0.022
|
|
CRP, mg/dL
|
10.5 (6.2–18.5)
|
9.83 (5.9–15.3)
|
10.5 (6.4–22.9)
|
0.666
|
|
PCT, ng/mL
|
9.4 (1.4–51.9)
|
17.1 (1.8–52.9)
|
5.70 (1.2–27.2)
|
0.39
|
|
WBC × 103/μL
|
10.7 (3.7–17.1)
|
14.0 (5.1–19.5)
|
7.4 (1.2–13.1)
|
0.153
|
|
Hct
|
29.8 (28.2–32.2)
|
30.8 (29.1–32.5)
|
28.6 (27.5–29.9)
|
0.09
|
|
PT-INR
|
1.38 (1.16–1.7)
|
1.39 (1.15–1.74)
|
1.29 (1.23–1.58)
|
0.624
|
|
FDP, μg/ml
|
16.4 (11.1–38.3)
|
14.5 (9.8–32.1)
|
22.6 (3.0–50.6)
|
0.321
|
|
BNP, pg/ml
|
432 (119–1168)
|
463 (128–1169)
|
248 (119–961)
|
0.767
|
|
AT3 activity, %
|
54 (45–66)
|
49 (39–63)
|
59 (50–75)
|
0.068
|
|
Focus of infection
|
|
Soft tissue, n
|
5
|
5
|
0
|
0.065
|
|
Respiratory, n
|
10
|
7
|
3
|
0.48
|
|
Central nervous system, n
|
2
|
1
|
1
|
> 0.999
|
|
Gastrointestinal, n
|
3
|
1
|
2
|
> 0.999
|
|
Hepatobiliary, n
|
5
|
2
|
3
|
0.633
|
|
Bacteremia or other, n
|
16
|
9
|
7
|
> 0.999
|
|
At the time of epinephrine infusion
|
|
MAP, mmHg
|
51.3 ± 11.2
|
52.1 ± 10
|
50.3 ± 13
|
0.613
|
|
PP, mmHg
|
24.7 ± 12
|
26.3 ± 11
|
22.5 ± 13
|
0.317
|
|
HR, bpm
|
107 ± 21
|
103 ± 21
|
113 ± 20
|
0.149
|
|
CVP, mm Hg
|
15 (12–17)
|
13 (11–17)
|
15 (13–18)
|
0.2
|
|
Lactate, mmol/L
|
4.4 (2.6–8.9)
|
3.4 (2.1–7.6)
|
6.0 (3.6–9.6)
|
0.098
|
|
pH
|
7.309 (7.386–7.181)
|
7.336 (7.212–7.386)
|
7.261 (7.098–7.386)
|
0.266
|
|
P-F ratio
|
163 (92–302)
|
222 (111–354)
|
131 (83–164)
|
0.093
|
|
Norepinephrine, μg/kg/min
|
0.2 (0.17–0.25)
|
0.19 (0.17–0.23)
|
0.25 (0.16–0.28)
|
0.467
|
|
Epinephrine, μg/kg/min*
|
0.07 (0.03–0.1)
|
0.05 (0.03–0.1)
|
0.08 (0.07–0.14)
|
0.068
|
|
Time-epi, h**
|
24 (12–72)
|
18 (12–24)
|
72 (6.0–144)
|
0.004
|
|
Adjunctive therapy
|
|
Fluid infusion, ml***
|
559 (426–808)
|
559 (418–762)
|
559 (447–958)
|
0.989
|
|
Corticosteroid, n (%)
|
35 (85)
|
20 (83)
|
15 (88)
|
> 0.999
|
|
Vasopressin, i (%)
|
20 (49)
|
10 (42)
|
10 (59)
|
0.35
|
|
CRRT, n (%)
|
28 (68)
|
15 (63)
|
13 (76)
|
0.505
|
|
VA-ECMO, n (%)
|
3 (7)
|
0 (0)
|
3 (18)
|
0.006
|
|
Endpoints
|
|
ΔMAP after initiation, mmHg ****
|
13 (0–22)
|
20 (14–29)
|
-1 (− 7 to 6)
|
< 0.001
|
|
Lactate 3 h after initiation, mmol/L
|
6.4 (3.1–11.5)
|
4.2 (2.8–9.0)
|
11.4 (5.1–13.8)
|
0.039
|
|
Survival from shock, n (%) *****
|
25 (61)
|
22 (92)
|
3 (18)
|
< 0.001
|
|
28-day survival, n (%)
|
23 (56)
|
20 (83)
|
3 (18)
|
< 0.001
|
